Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Hospira

Novartis building

Novartis parts with Eisai to go it alone with COPD drugs

Ends co-promotion agreement for Onbrez, Seebri and QVA149

- PMLiVE

Amgen signs $180m nanotechnology cancer deal

Will combine BIND Biosciences' tissue-targeting technology with a molecularly-targeted drug

- PMLiVE

Pfizer acquires spinal muscular atrophy research programme

Gains rights to drug candidate RG3039 in deal with Repligen that could be worth up to $70m

- PMLiVE

NICE set to approve Novartis eye drug Lucentis

Final draft guidance says treatment is cost-effective in diabetic macular oedema

- PMLiVE

Eliquis and Ryzodeg feature among Japan’s year-end approvals

Actonel and Neupro also given green light

Novartis building

Novartis’ Exjade gets EU approval for thalassaemia

First oral treatment for condition characterised by red blood cell problems and anaemia

- PMLiVE

FDA clears six new drugs in time for the new year

Brings 2012 tally to 39 – the highest for more than 15 years

- PMLiVE

Amgen offers $762m to end Aranesp lawsuits

Pleads guilty to illegal marketing of anaemia drug

- PMLiVE

ViiV submits dolutegravir for approval to treat HIV in US, EU and Canada

GSK-Pfizer joint venture takes next step towards commercialisation

- PMLiVE

Year-end FDA approvals for Novartis, GSK drugs

Agency gives go-ahead to Cushing’s disease treatment Signifor and raxibacumab for inhalational anthrax

- PMLiVE

Amgen appoints CEO Robert Bradway to chair of board

Replaces Kevin Sharer who retires

- PMLiVE

Amgen continues spending spree, acquires deCode Genetics

Will pay $415m for Icelandic genetic information firm

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links